Image pharmaphorum Editor R&D 12 Questions with Dr Michelle Longmire As the co-founder and chief executive officer of Medable, Dr Michelle Longmire is mission-driven to accelerate the development of new therapies for disease. R&D Inside out – the coming of age of organ-on-a-chip technology Perhaps the most beautiful thing about pharmacology, and the healthcare industry at large, is the continued pursuit of new ideas and innovations. R&D Research & Development 2023 So, what does 2023 have in store for pharma R&D? R&D Strategies in securing funding for rare disease research An outline of emerging financing strategies for rare disease research in challenging times. Load more results
R&D 12 Questions with Dr Michelle Longmire As the co-founder and chief executive officer of Medable, Dr Michelle Longmire is mission-driven to accelerate the development of new therapies for disease.
R&D Inside out – the coming of age of organ-on-a-chip technology Perhaps the most beautiful thing about pharmacology, and the healthcare industry at large, is the continued pursuit of new ideas and innovations.
R&D Strategies in securing funding for rare disease research An outline of emerging financing strategies for rare disease research in challenging times.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.